Servicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Revista Med
versión impresa ISSN 0121-5256versión On-line ISSN 1909-7700
Resumen
LOPEZ GARZON, Nelson Adolfo y ADOLFO ANGEL, Gustavo. Heart failure with preserved ejection fraction: overview and perioperative management. Rev. Med [online]. 2020, vol.28, n.2, pp.49-60. Epub 04-Jun-2021. ISSN 0121-5256. https://doi.org/10.18359/rmed.4854.
Heart failure with preserved ejection fraction (HFPEF) is frequent and challenging to manage in the adult population during the perioperative period. It is a complex clinical syndrome with structural and functional cardiac abnormalities with left ventricular preserved ejection fraction (LVPEF) ≥ 50%. Biomarkers, echocardiography, cardiac catheterization, and other noninvasive methods confirm the diagnosis. Currently, there is no specific effective management compared to failure with reduced LVPEF.
Aim:
To prepare a literature review of HFpEF and its anesthetic implications.
Methods:
A non-systematic literature review was carried out in the following databases: Pubmed/Medline, LILACS, ScienceDirect.
Results:
HFpEF is a common entity with a prevalence between 36.9 % and more than 50 % of all patients. The pathophysiology includes diastolic alterations of the cardiac cycle, including relaxation and ventricular compliance phases. From the anesthetic point of view, sinus rhythm should be maintained in arrhythmias, chronotropic response controlled, pulmonary congestion avoided, etiologies/comorbidities specifically managed, ventricular filling pressures preserved, and hemodynamic stability achieved.
Conclusion:
Patients with HFPEF represent an anesthetic challenge. Management includes specific treatment of etiologies, comorbidities, and phenotypes. Unlike heart failure with reduced ejection fraction, there are no therapies that reduce mortality, so new drugs and clinical studies are required to improve anesthetic prospects and therapeutic management.
Palabras clave : preserved ejection fraction; heart failure; anesthesia; diastolic dysfunction; perioperative period.
